Cosmos Health achieves record 2025 revenue and dramatic gross profit growth
Cosmos Health (NASDAQ:COSM), a diversified global healthcare group, has announced record-breaking financial results for the fiscal year ended December 31, 2025.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Cosmos Health (NASDAQ:COSM), a diversified global healthcare group, has announced record-breaking financial results for the fiscal year ended December 31, 2025.
USA Rare Earth (NASDAQ:USAR) announced a major operational milestone on April 15, 2026, with the first commercial pour of yttrium metal at its subsidiary, Less Common Metals (LCM), located in Cheshire, UK.
Nixxy (NASDAQ:NIXX) has reported its financial results for fiscal year 2025, marking the successful conclusion of a multi-year strategic transformation.
Canaan (NASDAQ:CAN), a leading provider of high-performance computing solutions and a pioneer in Bitcoin mining hardware, has released its unaudited operational update for March 2026.
XTI Aerospace (NASDAQ:XTIA) has released its financial results for the full year 2025 and provided an optimistic outlook for 2026, marking its first comprehensive reporting period since the $40 million acquisition of Drone Nerds in late 2025.
Stereotaxis (NYSE:STXS), a pioneer in innovative robotic technologies for the treatment of arrhythmias and endovascular disease, announced today that it has entered into a definitive agreement to acquire Robocath.
Viant Technology (NASDAQ:DSP), a prominent player in AI-powered programmatic advertising, announced today that it has entered into a definitive agreement to acquire TVision Insights.
Raytheon, an RTX (NYSE:RTX) business, achieved a major milestone in its next-generation sensing portfolio on April 15, 2026, with the successful completion of the first flight test of the RAIVEN Staring sensing system.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) announced on April 15, 2026, a strategic partnership with Runway Health to make ARAKODA (tafenoquine) available to U.S. travelers via a dedicated telehealth platform.
Immutep (NASDAQ:IMMP), a clinical-stage biotechnology company developing LAG-3 immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, eftilagimod alfa (efti), for the treatment of soft tissue sarcoma (STS).
NOV (NYSE:NOV) announced today that it has lowered its financial guidance for the first quarter of 2026, citing unforeseen operational and logistical disruptions caused by the escalating conflict in the Middle East.
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company specializing in chronic infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV).
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade